Benign Prostatic Hyperplasia (BPH) is a common nonmalignant enlargement of the prostate gland, typically occurring in men around the age of 50. Because the prostate surrounds the urethra, its enlargement can lead to various urinary symptoms, including frequency, hesitancy, urgency, nocturia, and a weak urinary stream.
The management of BPH is not "one size fits all"; rather, it is highly individualized based on the severity of the patient's symptoms and the underlying physiological cause of the obstruction.
Understanding the Obstruction: Mechanical vs. Dynamic
To treat BPH effectively, clinicians must distinguish between the two types of obstruction that contribute to urinary symptoms:
- Mechanical Obstruction: This is caused by the physical overgrowth of epithelial cells, which increases pressure on the urethra and physically blocks urine flow.
- Dynamic Obstruction: This is caused by the overgrowth of smooth muscle cells, which results in thickened urethral walls and a loss of the ability to void effectively.
Clinical Management Strategies
The approach to BPH follows a tiered strategy based on clinical presentation:
- Asymptomatic or Mild Symptoms: Often managed with "watchful waiting," which includes yearly re-evaluations and lifestyle modifications such as avoiding alcohol.
- Moderate Symptoms: Pharmacotherapy is introduced to target either the mechanical or dynamic components of the obstruction.
- Severe Symptoms: If symptoms are debilitating, invasive procedures may be required. These include Transurethral electrovaporization of the prostate (TURP), High-density forced ultrasound (HIFU), or Transurethral needle ablation (TUNA).
Pharmacotherapy: 5-Alpha-Reductase Inhibitors
For patients experiencing mechanical obstruction due to a severely enlarged prostate, 5-alpha-reductase inhibitors are the preferred pharmacological intervention.
Keep reading for free.
Create an account to finish this reading and make it part of your study routine.
Continue reading freeAlready have an account? Log in
Updated